Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 24 (1), 30-42

Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review

Affiliations
Review

Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review

Arun T Nair et al. J Neurogastroenterol Motil.

Abstract

Recent investigations suggest that gut microbiota affects the brain activity through the microbiota-gut-brain axis under both physiological and pathological disease conditions like Parkinson's disease. Further dopamine synthesis in the brain is induced by dopamine producing enzymes that are controlled by gut microbiota via the microbiota-gut-brain axis. Also alpha synuclein deposition and the associated neurodegeneration in the enteric nervous system that increase intestinal permeability, oxidative stress, and local inflammation, accounts for constipation in Parkinson's disease patients. The trigger that causes blood brain barrier leakage, immune cell activation and inflammation, and ultimately neuroinflammation in the central nervous system is believed to be due to the chronic low-grade inflammation in the gut. The non-motor symptoms that appear years before motor symptoms could be reliable early biomarkers, if they could be correlated with the established and reliable neuroimaging techniques or behavioral indices. The future directions should therefore, focus on the exploration of newer investigational techniques to identify these reliable early biomarkers and define the specific gut microbes that contribute to the development of Parkinson's disease. This ultimately should pave the way to safer and novel therapeutic approaches that avoid the complications of the drugs delivered today to the brain of Parkinson's disease patients.

Keywords: Biomarkers; Constipation; Gastrointestinal microbiome; Humans alpha synuclein; Parkinson disease.

Conflict of interest statement

Conflicts of interest: None.

Figures

Figure
Figure
Gut inflammation driven gastrointestinal dysfunction mediated Parkinson’s disease (PD) pathogenesis model. BBB, blood brain barrier. Adapted from Yarandi et al and Houser and Tansey.

Similar articles

See all similar articles

Cited by 14 PubMed Central articles

See all "Cited by" articles

References

    1. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124:901–905. doi: 10.1007/s00702-017-1686-y. - DOI - PubMed
    1. Statistics on Parkinson’s disease. Parkinson Association of the Carolinas; [accessed 11 December, 2017]. Available from URL: http://www.parkinsonassociation.org/
    1. Schapira AH. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol. 2013;26:395–400. doi: 10.1097/WCO.0b013e3283633741. - DOI - PMC - PubMed
    1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912. doi: 10.1016/S0140-6736(14)61393-3. - DOI - PubMed
    1. Garcia-Ruiz PJ, Chaudhuri KR, Martinez-Martin P. Non-motor symptoms of parkinson’s disease a review from the past. J Neurol Sci. 2014;338:30–33. doi: 10.1016/j.jns.2014.01.002. - DOI - PubMed

LinkOut - more resources

Feedback